Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
- 30 November 2009
- journal article
- research article
- Published by Elsevier BV in Cancer Epidemiology
- Vol. 33 (5), 391-395
- https://doi.org/10.1016/j.canep.2009.10.005
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Anti‐tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft modelInternational Journal of Cancer, 2004
- Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cellsZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Angiotensin converting enzyme inhibitors for cancer treatment?Acta Oncologica, 2004
- Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trialsThe Lancet Oncology, 2003
- Inhibition of Tumor-Induced Angiogenesis and Matrix-Metalloproteinase Expression in Confrontation Cultures of Embryoid Bodies and Tumor Spheroids by Plant Ingredients Used in Traditional Chinese MedicineLaboratory Investigation, 2003
- Angiotensin-converting enzyme inhibitors and the risk of cancerCancer, 2001
- Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarctionAmerican Journal of Health-System Pharmacy, 2000
- The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatinProceedings of the National Academy of Sciences of the United States of America, 1997
- Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.JCI Insight, 1996
- Angiotensin-Converting Enzyme Inhibition Reduces Neuroblastoma Cell Growth RateExperimental Biology and Medicine, 1991